These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32562663)

  • 1. Sirt3 promotes hepatocellular carcinoma cells sensitivity to regorafenib through the acceleration of mitochondrial dysfunction.
    Wang R; Liu Y; Mi X; Chen Q; Jiang P; Hou J; Lin Y; Li S; Ji B; Fang Y
    Arch Biochem Biophys; 2020 Aug; 689():108415. PubMed ID: 32562663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway.
    Tao NN; Zhou HZ; Tang H; Cai XF; Zhang WL; Ren JH; Zhou L; Chen X; Chen K; Li WY; Liu B; Yang QX; Cheng ST; Huang LX; Huang AL; Chen J
    Oncotarget; 2016 Aug; 7(31):50117-50130. PubMed ID: 27367026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells.
    Tsai JJ; Pan PJ; Hsu FT
    Oncol Rep; 2017 Feb; 37(2):1036-1044. PubMed ID: 28000898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
    Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. {2-[1-(3-Methoxycarbonylmethyl-1H-indol-2-yl)-1-methyl-ethyl]-1H-indol-3-yl}-acetic acid methyl ester (MIAM) inhibited human hepatocellular carcinoma growth through upregulation of Sirtuin-3 (SIRT3).
    Li Y; Wang W; Xu X; Sun S; Qu XJ
    Biomed Pharmacother; 2015 Feb; 69():125-32. PubMed ID: 25661348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
    Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
    BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABT737 enhances ovarian cancer cells sensitivity to cisplatin through regulation of mitochondrial fission via Sirt3 activation.
    Hou L; Wang R; Wei H; Li S; Liu L; Lu X; Yu H; Liu Z
    Life Sci; 2019 Sep; 232():116561. PubMed ID: 31247208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1237-1245. PubMed ID: 25907508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MCU-dependent mitochondrial Ca
    Ren T; Zhang H; Wang J; Zhu J; Jin M; Wu Y; Guo X; Ji L; Huang Q; Zhang H; Yang H; Xing J
    Oncogene; 2017 Oct; 36(42):5897-5909. PubMed ID: 28650465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: Possible targets and future directions in the regorafenib era.
    Juengpanich S; Topatana W; Lu C; Staiculescu D; Li S; Cao J; Lin J; Hu J; Chen M; Chen J; Cai X
    Int J Cancer; 2020 Oct; 147(7):1778-1792. PubMed ID: 32162677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway.
    Wang J; Zhang N; Han Q; Lu W; Wang L; Yang D; Zheng M; Zhang Z; Liu H; Lee TH; Zhou XZ; Lu KP
    Cancer Lett; 2019 Mar; 444():82-93. PubMed ID: 30583078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
    Wu LW; Zhou DM; Zhang ZY; Zhang JK; Zhu HJ; Lin NM; Zhang C
    Biochem Biophys Res Commun; 2019 May; 512(4):852-858. PubMed ID: 30929918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minnelide/Triptolide Impairs Mitochondrial Function by Regulating SIRT3 in P53-Dependent Manner in Non-Small Cell Lung Cancer.
    Kumar A; Corey C; Scott I; Shiva S; D'Cunha J
    PLoS One; 2016; 11(8):e0160783. PubMed ID: 27501149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
    He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
    Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-walled carbon nanohorn aggregates promotes mitochondrial dysfunction-induced apoptosis in hepatoblastoma cells by targeting SIRT3.
    Li B; Chen X; Yang W; He J; He K; Xia Z; Zhang J; Xiang G
    Int J Oncol; 2018 Sep; 53(3):1129-1137. PubMed ID: 29956732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
    Liu S; Du Y; Ma H; Liang Q; Zhu X; Tian J
    Cancer Lett; 2019 Jul; 453():74-83. PubMed ID: 30928380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells.
    Paech F; Mingard C; Grünig D; Abegg VF; Bouitbir J; Krähenbühl S
    Toxicology; 2018 Feb; 395():34-44. PubMed ID: 29341879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of PI3K/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondrial-lysosomal crosstalk.
    Sheng J; Shen L; Sun L; Zhang X; Cui R; Wang L
    Cell Prolif; 2019 May; 52(3):e12609. PubMed ID: 31033054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of glycogen catabolism induces intrinsic apoptosis and augments multikinase inhibitors in hepatocellular carcinoma cells.
    Barot S; Abo-Ali EM; Zhou DL; Palaguachi C; Dukhande VV
    Exp Cell Res; 2019 Aug; 381(2):288-300. PubMed ID: 31128107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib.
    Zhuo J; Lu D; Lin Z; Yang X; Yang M; Wang J; Tao Y; Wen X; Li H; Lian Z; Cen B; Dong S; Wei X; Xie H; Zheng S; Shen Y; Xu X
    Cell Death Dis; 2021 Nov; 12(12):1084. PubMed ID: 34785656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.